Inograf (Tacrolimus) 0.5mg
₨1,550
Payment Methods:

Description
Inograf (Tacrolimus) 0.5mg – Essential Immunosuppressant for Transplant Success
Inograf (Tacrolimus) 0.5mg is a potent immunosuppressant used to prevent organ rejection in patients who have undergone kidney, liver, or heart transplants. It helps regulate the immune system, reducing the risk of the body attacking the transplanted organ, ensuring long-term transplant success.
Key Benefits of Inograf 0.5mg:
✅ Prevents Organ Rejection – Essential for post-transplant care
✅ Regulates Immune System – Reduces immune response to protect the transplanted organ
✅ Enhances Transplant Success – Helps maintain organ function
✅ Used in Combination Therapy – Often prescribed with other immunosuppressants
✅ Well-Tolerated & Effective – With proper dosage monitoring
How to Use Inograf (Tacrolimus) 0.5mg
- Take exactly as prescribed by your doctor, usually once or twice daily.
- Best taken on an empty stomach or 2 hours after a meal for optimal absorption.
- Swallow the capsule whole with water; do not crush or chew.
- Avoid grapefruit and grapefruit juice, as they can interfere with drug metabolism.
- Regular blood tests are necessary to monitor drug levels and adjust dosage.
- Report any side effects such as tremors, kidney issues, or infections to your doctor immediately.
Following your healthcare provider’s instructions is crucial for maintaining transplant success and overall health.
Inograf 0.5mg – Protecting your transplanted organ for a healthier future!
Customer Reviews
Related Products
Agcal-D calcium supplement
In stock
OSVID Calcium Vit D3 &Zinc
In stock
Zolopat Forte Eye drop 5ml
In stock
CONTACT DETAILS
- Shop #3,4 Chaudhary Plaza Dhama moor Main adiyala road Rawalpindi
-
03125059372
0515561209 - info@shazeenpharmacy.com
- Customer Support: 7 Days a Week, 10:00AM - 10:00PM
Quick Links
Useful Links
SUBSCRIBE OUR NEWSLETTER
Get the latest offers and promotions!
Copyright © 2025 Shazeen Chemist. All rights reserved.

Reviews
Clear filtersThere are no reviews yet.